Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL
Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).
The study enrolled 34 patients who received duvelisib across a variety of doses. At the dose selected for phase III studies, 25 mg twice daily, duvelisib demonstrated an overall response rate (ORR) of 72%, notes Flinn. Thirty-three percent of patients experienced a complete response (CR). Among patients specifically with follicular lymphoma (n = 13), the ORR was 69%, including a 38% CR rate.
The treatment is currently being explored in the phase II DYNAMO trial and the phase III DYNAMO+R trial for patients with NHL. DYNAMO will asses duvelisib as monotherapy and DYNAMO-R will combined the novel therapy with rituximab.
<<<
